Fortitude Family Office’s NovoCure NVCR Stock Holding History

Fortitude Family Office’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67K	Buy	+110	New	+$1.66K	﹤0.01%	1552
2025 Q3	–	Sell	-30	Closed	-$534	–	2094
2025 Q2	$534	Buy	+30	New	+$523	﹤0.01%	1775

Other funds holding NVCR

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Fortitude Family Office's NVCR Position: Q2 2026 in Review

Fortitude Family Office opened a new position in NovoCure (NVCR) in Q2 2026: 110 shares worth $1.67K. The stake represents ﹤0.01% of the portfolio and ranks #1552 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in NVCR as recently as Q2 2025.

Fortitude Family Office first reported a position in NVCR in Q2 2025 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Fortitude Family Office held 110 shares of NovoCure worth $1.67K as of Q2 2026.
NovoCure was a new Fortitude Family Office position in Q2 2026.
NovoCure made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1552 holding.
Fortitude Family Office first reported a position in NovoCure in Q2 2025 and has held it in 2 quarters since.
29 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.